Why Exicure Inc. is a High-Risk, High-Reward Investment: Stock Insights
Exicure Inc is an early-stage biotechnology company headquartered in Chicago, IL. They focus on developing nucleic acid therapies targeting ribonucleic acid (RNA) against validated targets for neurological disorders and hair loss. Their operations include in-house discovery and development efforts with a dedicated 30 000 sq. ft. facility for nucleic acid synthesis and screening. 6 employees.
Finance Performance and Ratios
Exicure’s financial performance has been challenging. As of the latest reports, the company has experienced significant losses. Key financial ratios include: Market Cap:$21 million (as of Nov 20, 2024)
Financial Ratios and Metrics. Return on Equity (ROE): -132.62%; Return on Assets (ROA): -26.52%; Debt/Equity Ratio: 3.52; Quick Ratio: 0.46; Current Ratio: 0.71.
Exicure Inc Stock Price Performance
Exicure’s stock price has exhibited substantial volatility. From November 15 to 25 this year, the stock price surged by an impressive 847.93%. However, over the past five years, the stock has experienced a significant decline of 72.06%.
Investment Insight
This is the lowest investment rating we have encountered. Despite this, over the past 12 months, the stock price has soared by 865.02% (as of the time of writing). This isn’t surprising given that the company is still in its infancy and relies entirely on shareholder capital for its operations. As it has yet to generate any cash flow, the stock price increase is driven solely by investor expectations. In such a scenario, predicting the future stock price is extremely challenging. However, we have taken the risk and provided a price forecast below.
Exicure Inc Stock Forecast**
| MIN/MAX | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| MIN | – | 3.43 | – | 35.65 | – |
| MAX | – | 15.49 | – | 160.89 | – |
When to buy?
Typically, we avoid investing in such „hyped” company stocks as there are plenty of opportunities to earn with much less risk. However, we recommend monitoring this company’s performance closely. Who knows? This ugly duckling may just transform into a beautiful swan.
Dividend Policy
Exicure does not have a dividend policy.
Conclusion
Exicure Inc. presents a unique but high-risk investment opportunity. With a stock price driven by investor expectations and a history of significant volatility, the company’s future performance remains highly unpredictable. While the recent surge in stock price is notable, the lack of cash flow and reliance on shareholder capital underscore the inherent risks. Investors are advised to monitor Exicure’s progress closely, as there is potential for substantial rewards if the company successfully navigates its early-stage challenges.
A cup of coffee from you for this excellent analysis.
Company’s Site.
More US Stocks.
*Investment analysis involves scrutinizing over 50 different criteria to assess a company's ability to generate shareholder value. This comprehensive approach includes tracking revenue, profit, equity dynamics, dividend payments, cash flow, debt and financial management, stock price trends, bankruptcy risk, F-Score, and more. These metrics are consolidated into a straightforward Investment Scoreboard, which effectively helps predict future stock price movements.
**Use the price forecast to manage the risk of your investments.